November 6, 2017 09:03 AM ESTUpdated 09:59 AM
News Briefing

No­var­tis pitch­es two new CAR-T ap­pli­ca­tions to EMA; J&J re­ports pos­i­tive da­ta for lu­pus pro­gram

John Carroll

Editor & Founder

→ Basel-based No­var­tis $NVS has pushed along a dou­ble-bar­reled ap­pli­ca­tion for its lead­ing CAR-T drug Kym­ri­ah (CTL019). The phar­ma gi­ant has ap­plied to the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times